OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Improving Current Treatments for Schizophrenia
Nadja P. Marić, Milica Jovičić, Marina Mihaljević, et al.
Drug Development Research (2016) Vol. 77, Iss. 7, pp. 357-367
Closed Access | Times Cited: 76
Nadja P. Marić, Milica Jovičić, Marina Mihaljević, et al.
Drug Development Research (2016) Vol. 77, Iss. 7, pp. 357-367
Closed Access | Times Cited: 76
Showing 26-50 of 76 citing articles:
Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies
Colm O’Tuathaigh, Paula M. Moran, Xuechu Zhen, et al.
British Journal of Pharmacology (2017) Vol. 174, Iss. 19, pp. 3173-3190
Open Access | Times Cited: 19
Colm O’Tuathaigh, Paula M. Moran, Xuechu Zhen, et al.
British Journal of Pharmacology (2017) Vol. 174, Iss. 19, pp. 3173-3190
Open Access | Times Cited: 19
Traditional Chinese Medicine Decoction Combined With Antipsychotic for Chronic Schizophrenia Treatment: A Systematic Review and Meta-analysis
Xiaojie Shi, Fangcheng Fan, Hua Liu, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 15
Xiaojie Shi, Fangcheng Fan, Hua Liu, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 15
Effects of brain-derived neurotrophic factor (BDNF) on the Schizophrenia model of animals
Xiaojie Shi, Yang Du, Lei-Chen, et al.
Journal of Psychiatric Research (2022) Vol. 156, pp. 538-546
Closed Access | Times Cited: 11
Xiaojie Shi, Yang Du, Lei-Chen, et al.
Journal of Psychiatric Research (2022) Vol. 156, pp. 538-546
Closed Access | Times Cited: 11
Lumateperone for the Treatment of Schizophrenia.
Amber N. Edinoff, Natalie W Wu, Charles deBoisblanc, et al.
Psychopharmacology bulletin (2020) Vol. 50, Iss. 4, pp. 32-59
Closed Access | Times Cited: 15
Amber N. Edinoff, Natalie W Wu, Charles deBoisblanc, et al.
Psychopharmacology bulletin (2020) Vol. 50, Iss. 4, pp. 32-59
Closed Access | Times Cited: 15
Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.
Amber N. Edinoff, Miriam T Ruoff, Yahya Ghaffar, et al.
Psychopharmacology bulletin (2020) Vol. 50, Iss. 4, pp. 83-117
Closed Access | Times Cited: 15
Amber N. Edinoff, Miriam T Ruoff, Yahya Ghaffar, et al.
Psychopharmacology bulletin (2020) Vol. 50, Iss. 4, pp. 83-117
Closed Access | Times Cited: 15
Behavioral and neurobiological changes in a novel mouse model of schizophrenia induced by the combination of cuprizone and MK-801
Zhengyu Sun, Li-Hong Gu, Denglei Ma, et al.
Brain Research Bulletin (2021) Vol. 174, pp. 141-152
Closed Access | Times Cited: 14
Zhengyu Sun, Li-Hong Gu, Denglei Ma, et al.
Brain Research Bulletin (2021) Vol. 174, pp. 141-152
Closed Access | Times Cited: 14
Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
Amber N. Edinoff, Prithvi Doppalapudi, Claudia Orellana, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 12
Amber N. Edinoff, Prithvi Doppalapudi, Claudia Orellana, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 12
Oleanolic acid alleviates the extrapyramidal symptoms and cognitive impairment induced by haloperidol through the striatal PKA signaling pathway in mice
Chang Hyeon Kong, Kyungnam Cho, Ji Won Min, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115639-115639
Open Access | Times Cited: 4
Chang Hyeon Kong, Kyungnam Cho, Ji Won Min, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115639-115639
Open Access | Times Cited: 4
Engineered PLGA microspheres for extended release of brexpiprazole: in vitro and in vivo studies
Bangqing Wu, Lijun Wu, Yingju He, et al.
Drug Development and Industrial Pharmacy (2021), pp. 1-10
Closed Access | Times Cited: 10
Bangqing Wu, Lijun Wu, Yingju He, et al.
Drug Development and Industrial Pharmacy (2021), pp. 1-10
Closed Access | Times Cited: 10
Schizophrenia interactome derived repurposable drugs and randomized control trials of two candidates
Madhavi K. Ganapathiraju, Triptish Bhatia, Smita Deshpande, et al.
Biological Psychiatry (2024)
Closed Access | Times Cited: 1
Madhavi K. Ganapathiraju, Triptish Bhatia, Smita Deshpande, et al.
Biological Psychiatry (2024)
Closed Access | Times Cited: 1
Peering into the mind: unraveling schizophrenia’s secrets using models
João V. Nani, Alysson R. Muotri, Mirian A.F. Hayashi
Molecular Psychiatry (2024)
Closed Access | Times Cited: 1
João V. Nani, Alysson R. Muotri, Mirian A.F. Hayashi
Molecular Psychiatry (2024)
Closed Access | Times Cited: 1
Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
Amber N. Edinoff, Natalie W Wu, Benjamin S. Maxey, et al.
PubMed (2021) Vol. 51, Iss. 2, pp. 69-95
Closed Access | Times Cited: 8
Amber N. Edinoff, Natalie W Wu, Benjamin S. Maxey, et al.
PubMed (2021) Vol. 51, Iss. 2, pp. 69-95
Closed Access | Times Cited: 8
Pharmacotherapy and Emerging Treatment Strategies for Schizophrenia
Jitendra Kumar Sinha, Punya Sachdeva, Faizan Ahmad, et al.
(2023), pp. 149-179
Closed Access | Times Cited: 3
Jitendra Kumar Sinha, Punya Sachdeva, Faizan Ahmad, et al.
(2023), pp. 149-179
Closed Access | Times Cited: 3
Effect of H2H management mode on blood sugar control and living ability in patients with schizophrenia and type 2 diabetes mellitus.
Lifeng Yang, Juan Wang, Han Li, et al.
PubMed (2023) Vol. 15, Iss. 1, pp. 223-232
Closed Access | Times Cited: 3
Lifeng Yang, Juan Wang, Han Li, et al.
PubMed (2023) Vol. 15, Iss. 1, pp. 223-232
Closed Access | Times Cited: 3
Inactivation of ERK1/2-CREB Pathway Is Implicated in MK801-induced Cognitive Impairment
Cuiping Guo, Wensheng Li, Yi Liu, et al.
Current Medical Science (2023) Vol. 43, Iss. 1, pp. 13-21
Closed Access | Times Cited: 3
Cuiping Guo, Wensheng Li, Yi Liu, et al.
Current Medical Science (2023) Vol. 43, Iss. 1, pp. 13-21
Closed Access | Times Cited: 3
DHF-7 Ameliorates Behavioral Disorders and White Matter Lesions by Regulating BDNF and Fyn in a Mouse Model of Schizophrenia Induced by Cuprizone and MK-801
Zhengyu Sun, Denglei Ma, Li-Hong Gu, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 7, pp. 600-612
Open Access | Times Cited: 5
Zhengyu Sun, Denglei Ma, Li-Hong Gu, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 7, pp. 600-612
Open Access | Times Cited: 5
A Review on Emerging Drug Targets in Treatment of Schizophrenia
Hemen S. Ved, Gaurav Doshi
Current Drug Targets (2020) Vol. 21, Iss. 15, pp. 1593-1605
Closed Access | Times Cited: 7
Hemen S. Ved, Gaurav Doshi
Current Drug Targets (2020) Vol. 21, Iss. 15, pp. 1593-1605
Closed Access | Times Cited: 7
Effect of individualized occupational therapy on social functioning in patients with schizophrenia: A five-year follow-up of a randomized controlled trial
Takeshi Shimada, Yusuke Inagaki, Yuko Shimooka, et al.
Journal of Psychiatric Research (2022) Vol. 156, pp. 476-484
Closed Access | Times Cited: 5
Takeshi Shimada, Yusuke Inagaki, Yuko Shimooka, et al.
Journal of Psychiatric Research (2022) Vol. 156, pp. 476-484
Closed Access | Times Cited: 5
Schizophrenia Aetiology and Drug Therapy: A Tale of Progressive Demystification and Strides in Management
Adejoke Y. Onaolapo, Olakunle J. Onaolapo
Advances in Pharmacology and Pharmacy (2018) Vol. 6, Iss. 2, pp. 19-42
Open Access | Times Cited: 6
Adejoke Y. Onaolapo, Olakunle J. Onaolapo
Advances in Pharmacology and Pharmacy (2018) Vol. 6, Iss. 2, pp. 19-42
Open Access | Times Cited: 6
Sexual Dysfunction in Schizophrenia: A Narrative Review of the Mechanisms and Clinical Considerations
Amber N. Edinoff, Catherine A. Nix, Juliana Fort, et al.
Psychiatry International (2021) Vol. 3, Iss. 1, pp. 29-42
Open Access | Times Cited: 6
Amber N. Edinoff, Catherine A. Nix, Juliana Fort, et al.
Psychiatry International (2021) Vol. 3, Iss. 1, pp. 29-42
Open Access | Times Cited: 6
The 5-HT6R agonist E-6837 and the antagonist SB-271046 reverse the psychotic-like behaviors induced by ketamine
José Eduardo Suárez-Santiago, Gabriel Roldán, Ofir Picazo
Behavioural Pharmacology (2022) Vol. 33, Iss. 4, pp. 249-254
Closed Access | Times Cited: 4
José Eduardo Suárez-Santiago, Gabriel Roldán, Ofir Picazo
Behavioural Pharmacology (2022) Vol. 33, Iss. 4, pp. 249-254
Closed Access | Times Cited: 4
Plasma Orexin-A Levels in Patients With Schizophrenia: A Systematic Review and Meta-Analysis
Shaoli Li, Ruili Zhang, Shaohua Hu, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 4
Shaoli Li, Ruili Zhang, Shaohua Hu, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 4
Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder
Junfa Gao, Junsheng Li, Xiuhua Lu, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 9, pp. 1011-1016
Closed Access | Times Cited: 3
Junfa Gao, Junsheng Li, Xiuhua Lu, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 9, pp. 1011-1016
Closed Access | Times Cited: 3
Art therapy as an adjuvant treatment for schizophrenia: A protocol for an updated systematic review and subgroup meta-analysis of randomized clinical trials following the PRISMA guidelines
Xuexing Luo, Zheyu Zhang, Zhong Zheng, et al.
Medicine (2022) Vol. 101, Iss. 40, pp. e30935-e30935
Open Access | Times Cited: 3
Xuexing Luo, Zheyu Zhang, Zhong Zheng, et al.
Medicine (2022) Vol. 101, Iss. 40, pp. e30935-e30935
Open Access | Times Cited: 3
BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)
Daniel Schöttle, Wolfgang Janetzky, François Therrien, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Daniel Schöttle, Wolfgang Janetzky, François Therrien, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 1
